Dupont Pharmaceuticals Company

Bristol-myers Squibb Pharma Company

Dupont Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Argyrios Georgios Arvanitis

Robert J Chorvat

Paul Joseph Gilligan

Liqi He

Richard Eric Olson

Rajagopal Bakthavatchalam

James Peter Beck

Gary Avonn Cain

Paul E Aldrich

Carl Nicholas Hodge

Zelda Rakowitz Wasserman

Robert Scott Cheeseman

William Eric Frietze

Charles R Arnold, Iii

Dimitri Emil Grigoriadis

Thomas E Christos

Paul John Krenitsky

Sang William Tam

Everett Latham Scholfield

Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Azolo triazines and pyrimidines

Arylamino fused pyridines

1N-alkyl-n-arylpyrimidinamines and derivatives thereof

Corticotropin releasing factor (CRF) antagonists of formula I or II:

Tetrazine bicyclic compounds

Corticotropin releasing factor (CRF) antagonists of Formula (I)

Triazinones and derivatives thereof

Corticotropin releasing factor (CRF) antagonists of Formula (I) ##STR1## and their use in treating psychiatric disorders and neurological diseases including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and eating disorders.

Pyrazinones and triazinones and their derivatives thereof

Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivityassociated with psychopathological disturbance andstress.

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.5, Z, Y, V, X, X', J, K, L, and M are as defined herein.

1N-alkyl-N-arylpyrimidinamines and derivatives thereof

Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.

Arylamino fused pyrimidines

Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Growing community of inventors

Kennett Square, PA, United States of America

Argyrios Georgios Arvanitis